CAIM
RXRX icon

Catherine Avery Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Catherine Avery Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.03K Hold
250
– – ﹤0.01% 159
2026
Q2 		$918 Buy
+250
New +$832 ﹤0.01% 158
2025
Q1 		– Sell
-70
Closed -$473 – 181
2024
Q4 		$473 Buy
+70
New +$471 ﹤0.01% 165

Other funds holding RXRX

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $464M AUM 21.88% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.14B AUM 18.43% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
TWM
TriaGen Wealth Management Calabasas, California $413M AUM 35.91% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Catherine Avery Investment Management's RXRX Position: Q3 2026 in Review

Catherine Avery Investment Management held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 250 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #159.

Catherine Avery Investment Management first reported a position in RXRX in Q4 2024 and has held it in 3 quarters since. 24 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Catherine Avery Investment Management held 250 shares of Recursion Pharmaceuticals worth $1.03K as of Q3 2026.
  • Catherine Avery Investment Management left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Catherine Avery Investment Management's portfolio in Q3 2026, its #159 holding.
  • Catherine Avery Investment Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 3 quarters since.
  • 24 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Catherine Avery Investment Management's 13F filing for Q3 2026, filed 14 Oct 2026.